News for ACADIA Pharmaceuticals Inc. (ACAD)

On March 5, 2025, Elizabeth Garofalo, Director at ACADIA Pharmaceuticals Inc (ACAD), sold 4,919 shares of the company, according to a SEC Filing. Following this

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

ACADIA Pharmaceuticals Inc (ACAD) and Saniona have announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending

Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers and FY2025 initial guidance.

On February 28, 2025, Baker Bros. Advisors LP executed a significant transaction involving BeOne Medicines Ltd (ONC). The firm reduced its holdings by 470,215 s

Total Revenue (Q4 2024): $259.6 million, up 12% year over year.Total Revenue (Full Year 2024): $957.8 million, up 32% from the prior year.DAYBUE Sales (Q4 2024

Feb 26, 2025 / 09:30PM GMTOperator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Shannon, and I will be

Jan 14, 2025 / 05:00PM GMTTessa Romero - JPMorgan Chase & Co - Analyst Welcome, everyone, to the 43rd Annual JPMorgan Healthcare Conference. My name is Tess Rom

Dec 03, 2024 / 03:15PM GMTYigal Nochomovitz - Citigroup Global Markets Inc. - Analyst Okay. Great. All right. Welcome, everyone. I'm Yigal Nochomovitz, one of t

May 16, 2024 / 04:20PM GMTTazeen Ahmad - BofA Securities, Research Division - MD in Equity Research & Research Analyst Joining us again at the Bank of America H

May 14, 2024 / 05:30PM GMTJason Nicholas Butler - JMP Securities LLC, Research Division - MD, Director of Healthcare Research & Equity Research Analyst Excited

ACADIA Pharmaceuticals Inc (ACAD) showcases a robust product portfolio with FDA-approved drugs NUPLAZID® and DAYBUEâ„¢.The company's market capitalization sto

ACADIA Pharmaceuticals Inc (ACAD) has announced its participation in a fireside chat at TD Cowen's 45th Annual Health Care Conference, scheduled for Wednesday,

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. ”œWe closed 2

Recent Acquisition by Baker Bros. Advisors LP On February 12, 2025, Baker Bros. Advisors LP executed a strategic stock transaction involving Sera Prognostics In

On December 31, 2024, Baker Bros. Advisors LP executed a significant transaction by acquiring an additional 832,432 shares of Immatics NV at a trade price of $7

Overview of the Recent Transaction On December 31, 2024, Baker Bros. Advisors LP made a strategic move by acquiring an additional 803,575 shares of Celcuity Inc

On December 31, 2024, Baker Bros. Advisors LP executed a noteworthy transaction by acquiring 2,981,983 shares of Candel Therapeutics Inc. This acquisition marks

On December 31, 2024, Baker Bros. Advisors LP executed a significant transaction involving Biomea Fusion Inc. The firm reduced its holdings in the biopharmaceut